RNA Aptamers: A Review of Recent Trends and Applications

被引:40
作者
Kang, Kyung-Nam [1 ]
Lee, Yoon-Sik [2 ]
机构
[1] KIPS Ctr, Korea Inst Intellectual Property, Seoul 135980, South Korea
[2] Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 151747, South Korea
来源
FUTURE TRENDS IN BIOTECHNOLOGY | 2013年 / 131卷
关键词
RNA aptamer; Therapeutic application; Social networks; FACTOR IXA INHIBITOR; IN-VITRO; INNOVATION; PERFORMANCE; TECHNOLOGY; PEGAPTANIB; SELECTION; AGE; PHARMACOKINETICS; DETERMINANTS;
D O I
10.1007/10_2012_136
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
RNA aptamers, small oligonucleotides derived by an in-vitro selection process called SELEX (Systematic Evolution of Ligands by EXperimental enrichment), are important candidates for therapeutic and diagnostic applications. RNA aptamers have high affinity and specificity for their target molecules. In this review, we describe methods for generating RNA aptamers (the SELEX technique and modified SELEX processes) and therapeutic applications for diseases such as neovascular age-related macular degeneration (AMD), inflammatory diseases, and obesity. We also analyze the social networks among researchers and organizations (universities, research institutes, firms, etc.) that are active in the pursuit of aptamer-based therapeutic approaches. This study provides relevant information on recent research trends in RNA aptamers.
引用
收藏
页码:153 / 169
页数:17
相关论文
共 57 条
[1]   The determinants of faculty patenting behavior: Demographics or opportunities? [J].
Azoulay, Pierre ;
Ding, Waverly ;
Stuart, Toby .
JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION, 2007, 63 (04) :599-623
[2]   Quantum dot - Aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer [J].
Bagalkot, Vaishali ;
Zhang, Liangfang ;
Levy-Nissenbaum, Etgar ;
Jon, Sangyong ;
Kantoff, Philip W. ;
Langer, Robert ;
Farokhzad, Omid C. .
NANO LETTERS, 2007, 7 (10) :3065-3070
[3]  
Baum JAC, 2000, STRATEGIC MANAGE J, V21, P267, DOI 10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO
[4]  
2-8
[5]  
BCC Research, 2010, BIO071A BCC RES
[6]   Lessons from innovation empirical studies in the manufacturing sector: A systematic review of the literature from 1993-2003 [J].
Becheikh, N ;
Landry, R ;
Amara, N .
TECHNOVATION, 2006, 26 (5-6) :644-664
[7]   Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury [J].
Bless, NM ;
Smith, D ;
Charlton, J ;
Czermak, BJ ;
Schmal, H ;
Friedl, HP ;
Ward, PA .
CURRENT BIOLOGY, 1997, 7 (11) :877-880
[8]   Aptamers come of age - at last [J].
Bunka, David H. J. ;
Stockley, Peter G. .
NATURE REVIEWS MICROBIOLOGY, 2006, 4 (08) :588-596
[9]   Development of aptamer therapeutics [J].
Bunka, David H. J. ;
Platonova, Olga ;
Stockley, Peter G. .
CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (05) :557-562
[10]   A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor [J].
Chan, M. Y. ;
Rusconi, C. P. ;
Alexander, J. H. ;
Tonkens, R. M. ;
Harrington, R. A. ;
Becker, R. C. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) :789-796